[Treatment of open cavernous pulmonary tuberculosis (author's transl)].
In two groups, each of 40 patients, with previously untreated cavernous pulmonary tuberculosis the following treatment schemes were compared in a randomised clinical study: isoniazid, ethambutol, and rifampicin (control group) and isoprodian with rifampicin (study group). Bacteriologic and radiographic parameters showed that in the study group the results were at least as good as in the control group. Symptoms of drug intolerance were equally rare in both groups.
D003622:Dapsone / Q000627:therapeutic use; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000627:therapeutic use; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D011515:Prothionamide / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D004338:Drug Combinations; D011515:Prothionamide; D004977:Ethambutol; D003622:Dapsone; D007538:Isoniazid; D012293:Rifampin
Behandlung der offen-kavernösen Lungentuberkulose. Vergleichende Studie mit dem Kombinationen Isoprodian und Rifampicin sowie Isoniazid, Ethambutol und Rifampicin.